Selumetinib is a MEK inhibitor indicated for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibromas (PNs). The gene discussed is MAP2K7; the disease is neurofibromatosis type 1.